Literature DB >> 11170044

Prevalence of markers of hepatitis B in the adult German population.

W Jilg1, B Hottenträger, K Weinberger, K Schlottmann, E Frick, A Holstege, J Schölmerich, K D Palitzsch.   

Abstract

The prevalence of hepatitis B virus markers was investigated in 5305 individuals considered to be representative for the adult German population. After adjustment of the data according to the age and sex distribution in the whole German population an anti-HBc prevalence of 8.71% (95% confidence interval, 7.94-9.48%) and an HBsAg carrier rate of 0.62% (95% confidence interval, 0.40-0.84%) were calculated. Anti-HBc prevalence increased with age from 4.12% in the youngest group to 15.66% in the 61-70-year-old. The percentage of HBsAg carriers showed a maximum of 1.12% in the 41-50-year-old individuals and decreased significantly in the older age groups. 1.40% (95% confidence interval, 1.08-1.72%) of individuals had anti-HBc only. There was a trend to higher rates of this pattern in males than in females; a significantly higher percentage of persons with anti-HBc only was found in anti-HBc-positive individuals below 31 years than in older individuals. Five participants with anti-HBc only (7.7%, or about 0.1% of the whole population) showed HBV-DNA despite the absence of HBsAg. 3.1% of anti-HBc positive individuals where also positive for anti-HCV, that was significantly higher than the percentage of anti-HCV-positives among persons without any HBV marker (0.46%). This study provides a comprehensive picture of the current hepatitis B situation in Germany, showing new data especially on the distribution of HBsAg in the general population and on the subgroup of individuals with anti-HBc only. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170044

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  14 in total

1.  Serological pattern "anti-HBc alone": characterization of 552 individuals and clinical significance.

Authors:  Antje Knöll; Arndt Hartmann; Harald Hamoshi; Karin Weislmaier; Wolfgang Jilg
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

Review 2.  Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues.

Authors:  Tiffany Wu; Ryan M Kwok; Tram T Tran
Journal:  Am J Gastroenterol       Date:  2017-10-31       Impact factor: 10.864

3.  [4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009].

Authors:  Markus Peck-Radosavljevic; Johann Deutsch; Peter Ferenci; Ivo Graziadei; Harald Hofer; Heidemarie Holzmann; Wolf-Dietrich Huber; Herman Laferl; Andreas Maieron; Rudolf Stauber; Wolfgang Vogel
Journal:  Wien Klin Wochenschr       Date:  2010-05-04       Impact factor: 1.704

4.  Transmission of hepatitis B in Hamburg, Germany, 1998-2002: a prospective, population-based study.

Authors:  R Diel; J Helle; R Gottschalk
Journal:  Med Microbiol Immunol       Date:  2005-03-15       Impact factor: 3.402

5.  Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany.

Authors:  Gabriele Kirchner; Georgi Kirovski; Alexandra Hebestreit; Jürgen Schölmerich; Hans Jürgen Schlitt; Oliver Stoeltzing; Claus Hellerbrand
Journal:  Int J Clin Exp Med       Date:  2010-06-10

6.  Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment.

Authors:  Yan Liu; Felicia Wu
Journal:  Environ Health Perspect       Date:  2010-02-19       Impact factor: 9.031

7.  Hepatitis B virus DNA in sera of blood donors and of patients infected with hepatitis C virus and human immunodeficiency virus.

Authors:  Fernando Lopes Gonçales; Josiane Silveira Felix Pereira; Claudia Da Silva; Glaucimari Roberto Thomaz; Maria Helena Postal Pavan; Viviane Cristina Fais; Luis Alberto Magna; Neiva Sellan Lopes Gonçales
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

8.  [Hepatitis (Hep-Net) competence network].

Authors:  H Wedemeyer; S Meyer; M P Manns
Journal:  Internist (Berl)       Date:  2004-04       Impact factor: 0.743

Review 9.  Clinical impact of occult hepatitis B virus infection in immunosuppressed patients.

Authors:  Evangelista Sagnelli; Mariantonietta Pisaturo; Salvatore Martini; Pietro Filippini; Caterina Sagnelli; Nicola Coppola
Journal:  World J Hepatol       Date:  2014-06-27

10.  Fulminant hepatitis following chemotherapy treatment for breast cancer.

Authors:  Ali Hakim Shoushtari; Robert A Shaw
Journal:  BMJ Case Rep       Date:  2013-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.